| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We focused on pharmacologically active component from marine organisms for the development of novel anti hepatitis C virus agent. Thus, we screened extracts of marine organisms by using HCV replicon system and showed that the extract from Amphimedon sp. inhibits HCV replication by suppressing viral helicase and protease activities. In this study, we attempted to purify and identify the active component of Amphimedon sp., but not purify and identify it. Additionally, we established a cell-based screening system in order to identify compounds inhibiting the HCV NS2/3 protease activity. We screened extracts of marine organisms by using this system, but not identify extracts of marine organisms inhibiting the HCV NS2/3 protease activity.
|
